Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer

University Hospital, Rouen200 enrolled

Overview

The primary purpose of the study is to confirm the results of previous study about the usefulness of the serum Carcinoembryonic antigen (CEA) kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer (J Clin Oncol 2008;26:3681-6). The secondary purpose is to evaluate the value of circulating free mutant DNA and circulating tumor cells (CTC) and their variations during the treatment.

Prospective cohort study of patients treated with systemic chemotherapy for unresectable metastatic colorectal cancer. The chemotherapy monitoring is currently based on radiological evaluation (RECIST criteria) and clinical evaluation. Circulating markers as CEA, free mutant DNA, CTC represent an alternative approach. A previous study on usefulness of the serum Carcinoembryonic antigen (CEA) kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer has been published (J Clin Oncol 2008;26:3681-6). The present study is designed to validate the previous data. The secondary purpose is to evaluate variations of free mutant DNA and CTC during the chemotherapy. Patients will be included prospectively in 4 centers in Normandy. All systemic chemotherapy and biotherapy validate in this clinical situation by the French National Cancer Institute (INCa) is accepted. Evaluation of response based on RECIST criteria will be performed every 3 months. Blood samples for CEA and CA 19-9 levels will be performed every courses of chemotherapy during first 3 months. Blood samples for detection of free mutant DNA and CTC will be performed at day 1 and 42 of chemotherapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

200

Conditions

Metastatic Colorectal Cancer

Interventions

Blood samplingOTHER

blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA

Eligibility

Sex: ALLMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has Stage IV colorectal adenocarcinoma histologically proved * Patient has at least one measurable lesion * Patient has performance status 0-2 on the WHO performance scale * Patient is male or female, and \> 18 years of age * Patient has agree to participate by giving written informed consent Exclusion Criteria: * Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

Locations (4)

Centre François Baclesse

Caen, France

University Hospital

Caen, France

Centre Frédéric Joliot

Rouen, France

University Hospital

Rouen, France

Outcomes

Primary Outcomes

Prediction of tumor progression

sensitivity and specificity of CEA kinetic to predict tumor progression at 3 months (RECIST)

Time frame: 3 months

Secondary Outcomes

Prediction of tumor response

sensitivity and specificity of CEA kinetic to predict tumor response at 3 months (RECIST)

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.